Precision BioSciences Announces U.S. Patent Office Reexamination of Cellectis Patents Involved in Litigation
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. today announced that the United States Patent and Trademark Office (PTO) has granted Precision’s requests for inter partes reexamination of U.S. Patent Nos. 6,610,545 (the ‘545 patent) and 7,309,605 (the ‘605 patent), which Cellectis SA (Alternext: ALCLS) has asserted against Precision in litigation. The two patents are owned by the Institut Pasteur and the Universite Pierre et Marie Curie, and licensed to Cellectis. Precision BioSciences previously announced that the PTO is reexamining related U.S. Patent Nos. 7,214,536 and 6,833,252.